Drug news
Farxiga to enter Type 1 Diabetes trial-AstraZeneca + Ono
AstraZeneca has announced a new Phase III study to determine if adding Farxiga ( dapagliflozin ) to insulin is a safe and effective therapy to improve glycemic control in patients with Type 1 Diabetes and is currently recruiting participants. Target enrollment is 768 patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.